# Centennial Perspective

# The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 2, 1959–1983

Patrick J. Murphy

*College of Pharmacy and Health Sciences, Butler University, Indianapolis, Indiana*

**ABSTRACT:**

In 25 years, drug metabolism research went from using subcellular particles of undefined content to an understanding of metabolism at the molecular level. The discoveries of cytochrome P450, enzyme induction, reactive intermediates, and genetic polymorphisms were milestones in the field. New publications from the American Society for Pharmacology and Experimental Therapeutics chronicled the discoveries and provided communications to advance the science of drug metabolism.

The development of drug metabolism research from 1959 to 1983 involved a greater expansion of knowledge than in all of the previous history of the field. Moving from the subcellular level to the molecular level involved a number of significant discoveries and the development of exciting new technologies. Recognition of the changing science was reflected in two new publications from the American Society for Pharmacology and Experimental Therapeutics (ASPET). *Molecular Pharmacology*, launched in 1965, focused on research at the enzyme and receptor level. Avram Goldstein was the founder of this journal and editor for its first three years. In 1973, ASPET launched *Drug Metabolism and Disposition* under the editorship of Ken Leibman. Ken served the society well, emphasizing scientific scholarship and diversity of ideas. He even provided short summaries of articles published in other journals when he thought they might be of interest. During his 10 years as editor, *Drug Metabolism and Disposition* became the premier publication in the field. In 1977, ASPET introduced the Bernard B. Brodie Award to "recognize outstanding original research contributions in drug metabolism and disposition" (http://www.aspet.org/public/awards/brodie_award.html). The recipients of this biennial award represent some of the most outstanding contributors to the progress of drug metabolism science.

As 1959 began, it was clear that the microsomal fraction of the homogenized liver cell consisted mainly of fragments of the endoplasmic reticulum (Palade and Siekkevitz, 1956).[1] This fraction contained both drug metabolizing activity and a unique red pigment that had some of the properties of a cytochrome (Murphy, 2008). Two major discoveries in the

early 1960s shaped the nature of research for the next 50 years. The discovery of P450 eventually led to an understanding of the enzymes involved in oxidative drug metabolism and the nature of the catalytic reaction. The discovery of the inducibility of those enzymes initiated the concept of the existence of multiple hepatic P450s and led to the research efforts aimed at deciphering the controlling mechanisms in DNA expression linked to drug metabolizing enzymes.

## Discovery of P450

The discovery of P450 and its function evolved from observations by Ryan and Engel that C-21 hydroxylations of progesterone and hydroxylated progesterones were catalyzed by a CO inhibitable enzyme in the adrenal cortex (Ryan and Engel, 1957). They characterized the reaction as belonging to the class of enzymes categorized by Mason as "mixed-function oxidases" (Mason, 1957) and by Hayaishi as "oxygenases" (Hayaishi, 1962). These enzymes required molecular oxygen and a reductant such as NADPH. Although Ryan and Engel thought a cytochrome in the adrenal microsomes might be involved in the reaction, their methods did not permit measurement of the pigment in its active state. Meanwhile, the pigment in liver microsomes that had been shown to bind CO was isolated and characterized by Omura and Sato as a cytochrome, referred to as cytochrome P450 (Omura and Sato, 1962). The story of the experiments characterizing the microsomal cytochrome as the terminal oxidase for mixed function oxidases is best told by the participants. David Cooper has detailed the meandering path that led him from his role as a surgical resident to his interest in the response of animals to stress and to the studies on the biosynthesis of steroids in the adrenal gland (Cooper, 1973). Collaborating with Otto Rosenthal, Cooper was frustrated in his attempts to define the stoichiometry of the C-21 hydroxylation and shared his efforts with Ron Estabrook. Estabrook invited Cooper to the Johnson Research Foundation for what proved to be an exciting and productive collaboration. They solved the problem of the exact stoichiometry of the reaction (Cooper et al., 1963) and went on to study the nature of

---

[1] A historical overview of the isolation and identification of the intracellular components of the liver cell is found in the three Nobel Prize lectures of the pioneers in this field, Claude, de Duve, and Palade, which can be found online at http://nobelprize.org/nobel_prizes/medicine/laureates/1974.

---

**ABBREVIATIONS:** P450, cytochrome P450; 3-MC, 3-methylcholanthrene; HPLC, high-performance liquid chromatography; NMR, nuclear magnetic resonance; GC/MS, gas chromatograph/mass spectrometer; DPH, diphenylhydantoin.

the CO inhibitable reaction. In his detailed and enjoyable reminiscences presented on the occasion of his Brodie award, Ron Estabrook[2] has paid particular homage to the advances in instrumentation that allowed them to perform their groundbreaking experiments (Estabrook, 2003). The photochemical action spectrum of the CO inhibited adrenal microsomes proved that P450 was the oxygen carrier for this class of reactions, which included both steroid hydroxylation and the oxidation of a multitude of drugs and other xenobiotics. Their landmark papers provided the foundation for studies of P450 related reactions involved in an ever-expanding list of transformations (Estabrook et al., 1963; Cooper et al., 1965).

### Induction of Metabolizing Enzymes

The second major breakthrough regarding microsomal metabolism came with the observations by Alan Conney in the United States and H. Remmer and coworkers in Germany that microsomal activity could be stimulated by preadministration of various xenobiotics. Conney, working with James and Elizabeth Miller, found that polycyclic hydrocarbons could markedly increase the *N*-demethylation of the aminoazo dye 3-methyl-4-monomethylaminoazobenzene (Conney et al., 1956). Subsequent studies showed increases in drug metabolizing enzymes following induction by phenobarbital or 3,4 benzpyrene (Conney et al., 1960). Remmer and Merker also showed changes in enzyme activity and the endoplasmic reticulum in rabbits after treatment with phenobarbital and other drugs (Remmer and Merker, 1963). These discoveries stimulated the field and, by the time Conney wrote his classic review on induction, over 200 compounds had been shown to cause induction of the microsomal enzymes (Conney, 1967). Studies on the mechanisms of induction were initiated in this period. Poland and coworkers found a hepatic cytosol component that bound 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and other polycyclic hydrocarbons and suggested that it was the receptor for induction of aryl hydrocarbon hydroxylase (Poland et al., 1976). A summary of the advances was presented by Bresnick et al. in their 1984 review (Bresnick et al., 1984). Induction by both 3-methylcholanthrene (3-MC) and phenobarbital had been shown to involve increases in protein synthesis, RNA polymerase isozymes, and nuclear RNA precursors. The field was poised for breakthroughs in not only the understanding of P450 but also the factors controlling cellular activity at the most basic levels.

### Progress with P450

As the list of structurally diverse substrates for cytochrome P450 catalyzed oxidations grew, investigators became perplexed by the broad specificity of the enzyme system. The inability to free the enzyme system from the endoplasmic reticulum membrane without loss of activity severely hampered progress. Although the finding that a soluble, active P450 system was present in *Pseudomonas putida* (Katagiri et al., 1968) greatly advanced our understanding of the cytochrome and its structure, it did not shed light on the specificity of the mammalian system. Scientific meetings during this time were characterized by arguments about whether there was one P450 with membrane-controlled specificity or multiple P450s (maybe two!) lending various activities. The early evidence for at least 2 enzymes was mainly spectrophotometric. Imai and Sato found that, when microsomes were treated with ethyl isocyanide, two peaks were observed at 430 and 455 nm (Imai and Sato, 1966). The size of the

peaks was dependent on pH. Sladek and Mannering[3] looked at microsomes from inducer-treated animals and found that, after 3-MC induction, the ratio of the two peaks differed from that of control or phenobarbital induced rats (Sladek and Mannering, 1966). They suggested that there were at least two P450s. They referred to the 3-MC-induced form as $P_1$-450. Alvares and coworkers found that, after 3-MC induction, the peak absorbance of microsomes after reduction and addition of carbon monoxide was found at 448 nm rather than the 450 nm of the controls (Alvares et al., 1968). They termed this pigment P448. Schenkman, Remmer, and coworkers found that, when substrates or inhibitors were added to microsomes, there were spectral shifts (Remmer et al., 1966; Schenkman et al., 1967). These shifts were of two general types termed type I and type II. These spectral shifts were later shown to be related to the spin state of P450 iron (Kumaki et al., 1978).

The field struggled with the concept of one or two or more P450s for a number of years. In 1972, the second symposium on microsomes and drug oxidation was held at Stanford University. It was decided that this symposium would be an excellent first publication for the new ASPET journal, *Drug Metabolism and Disposition*. Browsing through this first volume gives good insight into the state of knowledge of P450 in 1972. There was evidence for two distinct forms of mammalian P450, and solubilization efforts were underway (Lu et al., 1973). The chemistry of P450 was being explored especially with the soluble P450 from *P. putida* (Lipscomb and Gunsalus, 1973). Studies on the mechanisms of P450 inhibitors (Gillette et al., 1973) and inducers (Conney et al., 1973) were presented. The meeting encompassed virtually all aspects of P450 research. The discussions were included in the publications, helping to illustrate the ongoing thought processes.

The initial breakthrough in solubilization of membrane-bound P450 came in Jud Coon's laboratory in the study of ω-hydroxylation of fatty acids.[4] Anthony Lu was able to obtain solubilized fractions of rabbit liver microsomes that consisted of lipid, P450, and reductase. When combined, these fractions were able to catalyze the ω-hydroxylation of lauric acid (Lu and Coon, 1968). Using variations of this methodology, it became possible to apply standard protein purification methods to P450s.[5] After his postdoctoral studies, Lu moved to Alan Conney's laboratory at Hoffman La-Roche and began a series of collaborative studies on the drug metabolizing system in liver microsomes. The solubilization and partial separation of cytochromes "P450" and "P448" showed that the substrate specificity of these preparations resided in the cytochrome fraction (Lu et al., 1972). These techniques, along with the application of immunological assays and SDS gel separation, led to the separation of six forms of P450 (Thomas et al., 1976).[6] Lu and West summarized the state of the art in the field in 1979, making the case for multiple P450s with species- and organ-specific forms (Lu and West, 1979). A unique inducible P450 was isolated from rats treated with pregnenolone-16α-carbonitrile (Elshourbagy and Guzelian, 1980). Guengerich and coworkers were able to isolate 8 P450 forms from rats pretreated with phenobarbital or β-naphthoflavone (Guengerich et al., 1982), and Wang et

---

[3] Gil Mannering has detailed his entrance into the field of drug metabolism and his work with microsomes and metabolism inhibitors in his 1984 Brodie award lecture (Mannering, 1986).

[4] Jud Coon discussed how his interest in fatty acid oxidation led him into the world of P450 and studies on the mechanism of P450 catalyzed oxidations in the 1980 Brodie award lecture (Coon, 1981).

[5] Anthony Lu has provided an overview of the work leading to solubilization of P450 and an understanding of its role in fatty acid and drug metabolism (Lu, 1998).

[6] The collaborative efforts leading to the resolution of rat liver P450s have been described in Wayne Levin's Brodie award lecture (Levin, 1990).

---

[2] A recent dedicatory volume honoring Ron Estabrook and his scientific contributions was published in *Drug Metabolism Reviews* **39:**251–646, 2007.

al. purified 6 P450s from human liver microsomes (Wang et al., 1983). The first amino acid sequence of a cytochrome P450 was determined by Fujii-Kuriyama and coworkers (Fujii-Kuriyama et al., 1982). As a prelude to our increased understanding of individual diversity, the relative levels of P450 forms in human liver were estimated by using warfarin metabolism as a diagnostic probe (Kaminsky et al., 1984). Soon the question changed from "more than one P450?" to "how many P450s?" The methodology available in 1983 for answering that question was beginning to show promise. The definitive answer, however, was to be found only after the molecular biological revolution occurring over the next 25 years.

### Biotransformation

The advances in technology during this period dramatically changed how and to what extent we were able to determine the structure of metabolites formed during the course of metabolism. Mass spectrometry moved from the hands of specialists to the analytical lab with the launch of the LKB 9000 GC/MS. Spectrometry in biological media became routine with the Cary 14 spectrophotometer and later with the Shimadzu (Kyoto, Japan) instrument containing larger photomultiplier tubes ideal for turbid solutions. Thin-layer chromatography came and went during this period, being displaced by gas chromatography and HPLC. The Varian (Palo Alto, CA) A-60, introduced in 1961, was the first widely accepted proton NMR instrument operating at 60 MHz. By 1983, a typical metabolism project used HPLC for separation and NMR and mass spectrometry for structure identification.

There were numerous studies on diphenylhydantoin (DPH) throughout this time period, and they provide a good picture of the changing technology. In 1960, Maynert examined the fate of DPH in dog, rat, and human (Maynert, 1960). He was expanding the findings of Butler that the main metabolite of DPH in human and dog was the *p*-hydroxylated analog (Butler, 1957). He prepared $^{15}$N-labeled DPH and assessed the excretion by isotopic dilution. Metabolites in ether extracts of urine were resolved by paper chromatography and, after derivatization by diazotized sulfanilic acid, eluted from the paper and monitored in a Beckman (Fullerton, CA) B spectrophotometer. His results showed that the *p*-HO-DPH and its glucuronide were the main products of metabolism. In 1970, Atkinson and coworkers found that meta-hydroxy DPH was actually the major primary metabolite of DPH in the dog (Atkinson et al., 1970). Atkinson used thin-layer chromatography followed by elution of selected zones from the plates and analysis of the methylated samples by GLC to identify the *meta*-substituted metabolite. This is still one of the most striking examples of species specificity in the literature. The dihydrodiol metabolite of DPH was initially reported by Chang et al. (Chang et al., 1970). Chang isolated the radiolabeled metabolite by silica column chromatography, countercurrent extraction, and thin-layer chromatography. The isolated metabolite was analyzed by IR, NMR, UV, and polarimetry. In a study of the absolute configuration of the dihydrodiol metabolites of DPH, they were isolated by extraction and preparative thin-layer chromatography and analyzed using optical rotatory dispersion, circular dichroism, and GC/MS of silylated derivatives (Maguire and Dudley, 1980). In 1983, evidence for an arene-3,4-oxide was obtained using deuterated DPH and isolating metabolites by HPLC and analyzing them by GC/MS (Moustafa et al., 1983). As with many other projects, our level of understanding advanced with the advances in technology. Yet, despite all these advances, metabolism scientists in 1983 were still dreaming of the direct combination of the separation powers of HPLC and the analytical powers of mass spectrometry.

Advances in analytical technology along with a greater understanding of the enzymes involved in transformation allowed exploration of the actual intermediates involved in metabolic pathways. A breakthrough in the understanding of aromatic hydroxylation came with the discovery of the "NIH shift." This reaction was characterized by the movement of hydrogen to an adjacent ring position during aromatic hydroxylation (Guroff et al., 1967). Jerina,[7] Daly, and others were able to demonstrate that an epoxide intermediate would explain the products of the microsomal oxidation of benzene and naphthalene (Jerina and Daly, 1974). This led to studies on polycyclic hydrocarbons and the unraveling of the diol-epoxide pathways. It is thought that the diol epoxide of benzo(a)pyrene is the ultimate carcinogenic metabolic of this potent carcinogen (Buening et al., 1978).

The formation of reactive intermediates and suicide substrates became a major area of research. The formation of "green pigments" during administration of 2-allyl-2-isopropylacetamide was shown by De Matteis to be due to destruction of P450 (De Matteis, 1971). Ethylene and other olefins were found to have similar destructive properties (Ortiz de Montellano and Mico, 1980). 1-Aminobenzotriazole was oxidized in microsomal incubations with concurrent loss of P450 (Ortiz de Montellano and Mathews, 1981). The progress on suicide inhibition of P450 was summarized by Ortiz de Montellano and Correia in 1983 (Ortiz de Montellano and Correia, 1983).[8]

The classic story of reactive intermediates and drug therapy arose from a series of studies on acetaminophen in Bernard Brodie's lab. In a series of four papers, Brodie and coworkers were able to show that 1) acetaminophen liver necrosis was dependent on the extent of metabolism and activity of P450 (Mitchell et al., 1973a), 2) acetaminophen liver necrosis was correlated with covalent binding of radiolabeled acetaminophen (Jollow et al., 1973), 3) radiolabeled acetaminophen was covalently bound to microsomes when metabolized by a P450-dependent reaction (Potter et al., 1973), and 4) the covalent binding of acetaminophen and hepatic necrosis was diminished by high levels of glutathione and exacerbated by depletion of glutathione levels (Mitchell et al., 1973b).

These studies are the basis for current studies on liver toxicity due to acetaminophen overdose, the effect of induction and inhibition on that toxicity, and the role of P450 forms in metabolism. In many respects, this system has become a model for all potential P450 interactions, and it is a staple at all drug metabolism scientific gatherings.

The role of glutathione as a precursor of mercapturic acids was confirmed in 1959 (Bray et al., 1959a,b), 80 years after the discovery of these important elimination products by Baumann and Preuss (1879). In the following 25 years, there were over 150 papers in the ASPET journals referring to aspects of glutathione in metabolism. The role of glutathione as a scavenger of reactive intermediates was of primary interest, as exemplified by the finding of the glutathione conjugate of acetaminophen by Hinson et al. (1982) or the formation of mercapturic acids from cyclohexene epoxide in the rat (van Bladeren et al., 1981).

It was becoming clear that, in the P450 system, there were multiple enzymes with the same mechanism but differing specificities. Once past that mental hurdle, it was necessary to deal with a second issue: the redundancy of enzyme types in the metabolism of a given class of compounds. Two significant examples illustrate this stretch in thinking. Ziegler and coworkers studied the *N*-oxidation of dimethylaniline

---

[7] Don Jerina was recipient of the third Brodie award. His Brodie lecture details the path from a puzzling retention of radioactivity during *p*-hydroxylation of *p*-labeled aromatic rings to the identification of dihydrodiol epoxides as ultimate carcinogenic moieties formed from benzo(a)pyrene and other aromatic hydrocarbons (Jerina, 1983).

[8] Paul R. Ortiz de Montellano has detailed the development of this field in his 1994 Brodie lecture (Ortiz de Montellano PR, 1995).

and found a flavin containing an enzyme free of heme that catalyzed the reaction (Machinist et al., 1968). Initial work was performed in pig liver but soon moved to other species, including humans (Ziegler and Gold, 1971). The enzyme was found to be distinct from other microsomal flavoproteins (Masters and Ziegler, 1971). This was a surprising finding, not only for Dan Ziegler[9] but also for many in the metabolism field who had ascribed that activity exclusively to the P450 system (Ziegler, 1991). The second example of expanding the thought process came from the lab of Charles Lieber. Rubin and Lieber found that ethanol was an inducer of the microsomal oxidizing system (Rubin and Lieber, 1968). Lieber went on to describe a microsomal system capable of oxidizing ethanol (Lieber and DeCarli, 1970) and to show that the metabolism of ethanol by this system was a significant factor in ethanol disposition (Lieber and DeCarli, 1972, 1973). In 1977, a reconstituted P450 system was shown to oxidize ethanol (Ohnishi and Lieber, 1977). This finding silenced skeptics who had doubted the relevance of the earlier findings. In both of these examples, the lesson of keeping an open mind to new discoveries was brought home with sound data and determination.

The establishment of the role of P450 in metabolism indicated that variability in metabolism between and within species could be caused by different numbers of P450s or P450s differing in structure, specificity, activity, or any combination of these. A new aspect of variability was uncovered in the labs of R. Smith and M. Eichelbaum. Smith's group found that a significant portion of humans (including R. Smith) were deficient in the ability to hydroxylate debrisoquine (Mahgoub et al., 1977). It had previously been shown that 4-hydroxylation was the major pathway of debrisoquine metabolism in humans (Allen et al., 1975). Eichelbaum's group had similar findings using sparteine (Eichelbaum et al., 1978). This genetic deficiency, which was soon to be traced to P450, opened a new era in our understanding of the role of P450 (Davies et al., 1981). Examination of additional drugs both old (Boobis et al., 1983; Mellström et al., 1983) and new (Wang et al., 1984) helped to expand the numbers of agents affected by this genetic polymorphism. The P450 catalyzing the reaction was isolated using specific antibodies and electrophoretic separation (Distlerath and Guengerich, 1984).

The discovery of P-glycoprotein in 1976 and its subsequent purification in 1979 was the opening of a new area of research in the study of drug disposition (Juliano and Ling, 1976; Riordan and Ling, 1979). The magnitude of the contribution of transporters to drug effectiveness and/or toxicity would only be realized with the soon to be explosive growth of this field.

In 25 years, the science of drug metabolism had moved from struggling with membrane preparations to an understanding of the molecules involved in transforming drugs and foreign substances. Methodology for separation and identification of metabolites and intermediates had been greatly improved and had great potential for even further advances. Scientists were asking new questions regarding human variability in metabolism. The P450 field had moved rapidly and was getting cluttered with enzymes of varying terminology. If only someone would invent a nomenclature system to systematize further research! With so many questions answered, it would seem that the field was at a peak. However, as with all science, the greater the knowledge, the more numerous and sophisticated the next generation of questions.

### References

Allen JG, East PB, Francis RJ, and Haigh JL (1975) Metabolism of debrisoquine sulfate: identification of some urinary metabolites in rat and man. *Drug Metab Dispos* **3:**332–337.

---

[9] Dan Ziegler looks back on the discovery of the flavin monooxygenase system in his Brodie award lecture (Ziegler, 1991).

Alvares AP, Schilling G, Levin W, and Kuntzman R (1968) Alteration of the microsomal hemoprotein by 3-methylcholanthrene; effects of ethionine and actinomycin D. *J Pharmacol Exp Ther* **163:**417–424.

Atkinson AJ Jr, MacGee J, Strong J, Garteiz D, and Gaffney TE (1970) Identification of 5-meta-hydroxyphenyl-5-phenylhydantoin as a metabolite of diphenylhydantoin. *Biochem Pharmacol* **19:**2483–2491.

Baumann E and Preuss C (1879) Ueber Bromphenylmercaptursaure. *Ber deut chem Ges* **12:**806–810.

Boobis AR, Murray S, Kahn GC, Robertz GM, and Davies DS (1983) Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. *Mol Pharmacol* **23:**474–481.

Bray HG, Franklin TJ, and James SP (1959a) The formation of mercapturic acids. 2. The possible role of glutathionase. *Biochem J* **71:**690–696.

Bray HG, Franklin TJ, and James SP (1959b) The formation of mercapturic acids. 3. N-acetylation of S-substituted cysteines in the rabbit, rat and guinea pig. *Biochem J* **73:**465–473.

Bresnick E, Foldes R, and Hines RN (1984) Induction of cytochrome P450 by xenobiotics. *Pharmacol Rev* **36:**43S–51S.

Buening MK, Wislocki PG, Levin W, Yagi H, Thakker DR, Akagi H, Koreeda M, Jerina DM, Conney AH (1978) Tumorigenicity of the optical enantiomers of the diastereomeric benzo-[a]pyrene 7,8-diol-9,10-epoxides in newborn mice: exceptional activity of (+)-7beta,8alpha-dihydroxy-9alpha,10alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. *Proc Natl Acad Sci U S A* **75:**5358–5361.

Butler TC (1957) The metabolic conversion of 5,5-diphenyl hydantoin to 5-(p-hydroxyphenyl)-5-phenyl hydantoin. *J Pharmacol Exp Ther* **119:**1–11.

Chang T, Savory A, and Glazko AJ (1970) A new metabolite of 5,5-diphenylhydantoin (Dilantin). *Biochem Biophys Res Commun* **38:**444–449.

Conney AH (1967) Pharmacological implications of microsomal enzyme induction. *Pharmacol Rev* **19:**317–366.

Conney AH, Davis C, Gastel R, and Burns JJ (1960) Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs. *J Pharmacol Exp Ther* **130:**1–8.

Conney AH, Lu AYH, Levin W, Somogyi A, West S, Jacobson M, Ryan D, and Kuntzman R (1973) Effect of enzyme inducers on substrate specificity of the cytochromes P-450's. *Drug Metab Dispos* **1:**199–210.

Conney AH, Miller EC, and Miller JA (1956) The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. *Cancer Res* **16:**450–459.

Coon M (1981) The 1980 Bernard B. Brodie award lecture. Drug metabolism by cytochrome P-450: progress and perspectives. *Drug Metab Dispos* **9:**1–4.

Cooper DY (1973) Discovery of the function of the heme protein P-450: a systematic approach to scientific research. *Life Sci* **13:**1151–1161.

Cooper DY, Estabrook RW, and Rosenthal O (1963) The stoichiometry of C21 hydroxylation of steroids by adrenocortical microsomes. *J Biol Chem* **238:**1320–1323.

Cooper DY, Levin S, Narasimhulu S, Rosenthal O, and Estabrook RW (1965) Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. *Science* **147:**400–402.

Davies DS, Kahn GC, Murray S, Brodie MJ, and Boobis AR (1981) Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. *Br J Clin Pharmacol* **11:**89–91.

De Matteis F (1971) Loss of haem in rat liver caused by the porphyrogenic agent 2-allyl-2-isopropylacetamide. *Biochem J* **124:**767–777.

Distlerath LM and Guengerich FP (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. *Proc Natl Acad Sci U S A* **81:**7348–7352.

Eichelbaum M, N Spannbrucker, and HJ Dengler (1978) A probably genetic defect of the metabolism of sparteine, in *Biological Oxidation of Nitrogen* (Gorrod JW, ed) pp 113–118, Elsevier/North Holland Biomedical Press, Amsterdam.

Elshourbagy NA and Guzelian PS (1980) Separation, purification, and characterization of a novel form of hepatic cytochrome P-450 from rats treated with pregnenolone-16 alpha-carbonitrile. *J Biol Chem* **255:**1279–1285.

Estabrook RW (2003) A passion for P450s (remembrances of the early history of research on Cytochrome P450). *Drug Metab Dispos* **31:**1461–1473.

Estabrook RW, Cooper DY, and Rosenthal O (1963) The light-reversible carbon monoxide inhibition of the steroid C-21 hydroxylation system of the adrenal cortex. *Biochem Z* **338:**741–755.

Fujii-Kuriyama Y, Mizukami Y, Kawajiri K, Sogawa K, and Muramatsu M (1982) Primary structure of a cytochrome P-450: coding nucleotide sequence of phenobarbital-inducible cytochrome P-450 cDNA from rat liver. *Proc Natl Acad Sci U S A* **79:**2793–2797.

Gillette J, Sasame H, and Stripp B (1973) Mechanisms of inhibition of drug metabolic reactions. *Drug Metab Dispos* **1:**164–175.

Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS (1982) Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. *Biochemistry* **21:**6019–6030.

Guroff G, Daly JW, Jerina DM, Renson J, Witkop B, Udenfriend S (1967) Hydroxylation-induced migration: the NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. *Science* **157:**1524–1530.

Hayaishi O (1962) History and scope, in *Oxygenases*, pp 1–29, Academic Press, New York.

Hinson JA, Monks TJ, Hong M, Highet RJ, and Pohl LR (1982) 3-(Glutathion-S-yl)acetaminophen: a biliary metabolite of acetaminophen. *Drug Metab Dispos* **10:**47–50.

Imai Y and Sato R (1966) Evidence for two forms of P-450 hemoprotein in microsomal membranes. *Biochem Biophys Res Commun* **23:**5–11.

Jerina DM (1983) The 1982 Bernard B. Brodie award lecture. Metabolism of aromatic hydrocarbons by the cytochrome P-450 system and epoxide hydrolase. *Drug Metab Dispos* **11:**1–4.

Jerina DM and Daly JW (1974) Arene oxides: a new aspect of drug metabolism. *Science* **185:**573–582.

Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, and Brodie BB (1973) Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. *J Pharmacol Exp Ther* **187:**195–202.

Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta* **455:**152–162.

Kaminsky LS, Dunbar DA, Wang PP, Beaune P, Larrey D, Guengerich FP, Schnellmann RG,

and Sipes IG (1984) Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. *Drug Metab Dispos* **12:**470–477.

Katagiri M, Ganguli BN, Gunsalus IC (1968) A soluble cytochrome P-450 functional in methylene hydroxylation. *J Biol Chem* **243:**3543–3546.

Kumaki K, Sato M, Kon H, and Nebert DW (1978) Correlation of type I, type II, and reverse type I difference spectra with absolute changes in spin state of hepatic microsomal cytochrome P-450 iron from five mammalian species. *J Biol Chem* **253:**1048–1058.

Levin W (1990) The 1988 Bernard B. Brodie award lecture. Functional diversity of hepatic cytochromes P450. *Drug Metab Dispos* **18:**824–830.

Lieber CS and DeCarli LM (1970) Hepatic microsomal ethanol-oxidizing system. In vitro characteristics and adaptive properties in vivo. *J Biol Chem* **245:**2505–2512.

Lieber CS and DeCarli LM (1972) The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo. *J Pharmacol Exp Ther* **181:**279–287.

Lieber CS and DeCarli LM (1973) The significance and characterization of hepatic microsomal ethanol oxidation in the liver. *Drug Metab Dispos* **1:**428–440.

Lipscomb JD and Gunsalus IC (1973) Structural aspects of the active site of cytochrome P-450cam. *Drug Metab Dispos* **1:**1–5.

Lu AY and West SB (1979) Multiplicity of mammalian microsomal cytochromes P-450. *Pharmacol Rev* **31:**277–295.

Lu AY (1998) The 1996 Bernard B. Brodie lecture. A journey in cytochrome P450 and drug metabolism research. *Drug Metab Dispos* **26:**1168–1173.

Lu AY, Coon MJ (1968) Role of hemoprotein P450 in fatty acid ω-hydroxylation in a soluble enzyme system from liver microsomes. *J Biol Chem* **243:**1331–1332.

Lu AY, Kuntzman R, West S, Jacobson M, Conney AH (1972) Reconstituted liver microsomal enzyme system that hydroxylates drugs, other foreign compounds, and endogenous substrates. II. Role of the cytochrome P-450 and P-448 fractions in drug and steroid hydroxylations. *J Biol Chem* **247:**1727–1734.

Lu AYH, Levin W, West SB, Jacobson M, Ryan D, Kuntzman R, and Conney AH (1973) Reconstituted liver microsomal enzyme system that hydroxylates drugs, other foreign compounds, and endogenous substrates. VI. Different substrate specificities of the cytochrome P450 fractions from control and phenobarbital-treated rats. *J Biol Chem* **248:**456–460.

Machinist JM, Dehner EW, and Ziegler DM (1968) Microsomal oxidases. 3. Comparison of species and organ distribution of dialkylarylamine N-oxide dealkylase and dialkylarylamine N-oxidase. *Arch Biochem Biophys* **125:**858–864.

Maguire JH, Butler TC, and Dudley KH (1980) Absolute configurations of the dihydrodiol metabolites of 5,5-diphenylhydantoin (phenytoin) from rat, dog, and human urine. *Drug Metab Dispos* **8:**325–331.

Mahgoub A, Idle JR, Dring LG, Lancaster R, and Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. *Lancet* **2:**584–586.

Mannering GJ (1986) The 1984 Bernard B. Brodie award lecture. From morphine to interferon: an odyssey of drug metabolism. *Drug Metab Dispos* **14:**1–4.

Mason H (1957) Mechanisms of oxygen metabolism. *Adv Enzymol Relat Subj Biochem* **19:**79–233.

Masters BS and Ziegler DM (1971) The distinct nature and function of NADPH-cytochrome c reductase and the NADPH-dependent mixed-function amine oxidase of porcine liver microsomes. *Arch Biochem Biophys* **145:**358–364.

Maynert EW (1960) The metabolic fate of diphenylhydantoin in the dog, rat and man. *J Pharmacol Exp Ther* **130:**275–284.

Mellström B, Bertilsson L, Birgersson C, Goransson M, and von Bahr C (1983) E- and Z-10-hydroxylation of nortriptyline by human liver microsomes—methods and characterization. *Drug Metab Dispos* **11:**115–119.

Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, and Brodie BB (1973a) Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. *J Pharmacol Exp Ther* **187:**185–194.

Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, and Brodie BB (1973b) Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathioone. *J Pharmacol Exp Ther* **187:**211–217.

Moustafa MA, Claesen M, Adline J, Vandervorst D, Poupaert JH (1983) Evidence for an arene-3,4-oxide as a metabolic intermediate in the meta- and para-hydroxylation of phenytoin in the dog. *Drug Metab Dispos* **11:**574–580.

Murphy PJ (2008) The development of drug metabolism research as expressed in the publications of ASPET: part 1, 1909–1958. *Drug Metab Dispos* **36:**1–5.

Ohnishi K and Lieber CS (1977) Reconstitution of the microsomal ethanol-oxidizing system. Qualitative and quantitative changes of cytochrome P-450 after chronic ethanol consumption. *J Biol Chem* **252:**7124–7131.

Omura T and Sato R (1962) A new cytochrome in liver microsomes. *J Biol Chem* **237:**1375–1376.

Ortiz de Montellano PR (1995) The 1994 Bernard B Brodie award lecture: Structure, Mechanism, and inhibition of Cytochrome P-450. *Drug Metab Dispos* **23:**1181–1187.

Ortiz de Montellano PR and Correia MA (1983) Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. *Annu Rev Pharmacol Toxicol* **23:**481–503.

Ortiz de Montellano PR and Mathews JM (1981) Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. *Biochem J* **195:**761–764.

Ortiz de Montellano PR and Mico BA (1980) Destruction of cytochrome P-450 by ethylene and other olefins. *Mol Pharmacol* **18:**128–135.

Palade GE and Siekkevitz P (1956) Liver microsomes; an integrated morphological and biochemical study. *J Biophys Biochem Cytol* **2:**171–200.

Poland A, Glover E, and Kende AS (1976) Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. *J Biol Chem* **251:**4936–4946.

Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, and Brodie BB (1973) Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro. *J Pharmacol Exp Ther* **187:**203–210.

Remmer H and Merker HJ (1963) Drug-induced changes in the liver endoplasmic reticulum: association with drug-metabolizing enzymes. *Science* **142:**1657–1658.

Remmer H, Schenkman J, Estabrook RW, Sasame H, Gillette J, Narasimhulu S, Cooper DY, and Rosenthal O (1966) Drug interaction with hepatic microsomal cytochrome. *Mol Pharmacol* **2:**187–190.

Riordan JR and Ling V (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. *J Biol Chem* **254:**12701–12705.

Rubin E and Lieber CS (1968) Hepatic microsomal enzymes in man and rat: induction and inhibition by ethanol. *Science* **162:**690–691.

Ryan KJ and Engel LL (1957) Hydroxylation of steroids at carbon 21. *J Biol Chem* **225:**103–114.

Schenkman JB, Remmer H, and Estabrook RW (1967) Spectral studies of drug interaction with hepatic microsomal cytochrome. *Mol Pharmacol* **3:**113–123.

Sladek NE and Mannering GJ (1966) Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene-treated rats. *Biochem Biophys Res Commun* **22:**668–674.

Thomas PE, Lu AYH, Ryan D, West SB, Kawalek J, and Levin W (1976) Immunochemical evidence for six forms of rat liver cytochrome P-450 using antibodies against purified rat liver cytochromes P-450 and P-448. *Mol Pharmacol* **12:**746–758.

van Bladeren PJ, Breimer DD, Seghers CJ, Vermeulen NP, van der Gen A, and Cauvet J (1981) Dose-dependent stereoselectivity in the formation of mercapturic acids from cyclohexene oxide by the rat. *Drug Metab Dispos* **9:**207–211.

Wang PP BP, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D, and Guengerich FP (1983) Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. *Biochemistry* **22:**5375–5383.

Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJ, and Wilkinson GR (1984) Influence of genetic polymorphism on the metabolism and disposition of encainide in man. *J Pharmacol Exp Ther* **228:**605–611.

Ziegler DM (1991) The 1990 Bernard B. Brodie award lecture. Unique properties of the enzymes of detoxication. *Drug Metab Dispos* **19:**847–852.

Ziegler DM and Gold MS (1971) Oxidative metabolism of tertiary amine drugs by human liver tissue. *Xenobiotica* **1:**325–326.

**Address correspondence to:** Dr. Patrick J. Murphy, 3589 Brumley Mews, Carmel, IN 46033. E-mail: pjmurphy12@aol.com